In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden

@article{Blijlevens2013InAH,
  title={In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient’s burden},
  author={Nicole M. A. Blijlevens and M de Ch{\^a}teau and Gregerly Krivan and Werner Rabitsch and Andras Szomor and Robert Pytl{\'i}k and Agneta Lissmats and Hans Erik Johnsen and T J M de Witte and Hermann Einsele and Tapani Ruutu and Dietger Niederwieser},
  journal={Bone Marrow Transplantation},
  year={2013},
  volume={48},
  pages={966-971}
}
This randomized-controlled trial studied the efficacy of palifermin in a chemotherapy-only, high-dose Melphalan (HDM) transplant setting, to reduce oral mucositis (OM) and its sequelae measured by patient-reported outcomes (PRO) and medical resource use. Palifermin, relative to placebo was given either pre-/post-HDM or pre-HDM in patients with multiple myeloma (MM) undergoing auto-SCT at 39 European centers. Oral cavity assessment (WHO) and PRO questionnaires (oral mucositis daily questionnaire… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

A recombinant human keratinocyte growth factor , triggers reactivation of anogenital human papillomavirus infection in a HIV - positive patient with diffuse large cell B - cell non - Hodgkin lymphoma

  • T Schroeder, F Zohren, C Saure, G Kobbe, Palifermin HaasR
  • Bone Marrow Transplant
  • 2010

Similar Papers

Loading similar papers…